# Intra- and extrapulmonary lipopolysaccharides-induced acute lung injury and pharmacotherapeutic response patterns in ventilated 7-day-old rabbits

**Authors:** Guiyin Zhuang, Qiang Gu, Siyu Xie, Xiaojing Guo, Bo Sun

PMC · DOI: 10.3389/ebm.2026.10788 · Experimental Biology and Medicine · 2026-02-24

## TL;DR

This study examines how different routes of LPS administration affect lung injury and treatment outcomes in young rabbits, finding that survival and lung function depend on the route of LPS exposure.

## Contribution

The study introduces a novel infant rabbit model to investigate LPS-induced lung injury and evaluates surfactant and inhaled nitric oxide treatment responses in pediatric acute respiratory distress.

## Key findings

- Survival rates depend on the route of LPS administration, not the dose.
- Intratracheal LPS caused higher lung injury scores and lower phospholipid pools compared to intravenous LPS.
- Combined surfactant and inhaled nitric oxide treatment showed mixed efficacy, with some groups showing worsened outcomes like metabolic acidosis and multiorgan inflammation.

## Abstract

We explored pharmacotherapeutic response patterns of lipopolysaccharides (LPS)-induced pneumonia and sepsis as direct and indirect acute lung injury (ALI), and efficacy of a combined surfactant (S) and inhaled nitric oxide (iNO), simulating critical care, in rabbits of post-neonatal infancy. Anaesthetized 7-day-old healthy rabbits were injected intratracheally (IT) or intravenously (IV) with LPS (15–20–25 mg/kg, L) or saline as a control (C), and subjected to initial 2-hour mechanical ventilation (MV) with standardized tidal volume to induce ALI. They were then treated with S (200 mg/kg) and iNO (10 ppm, N), or not, thereby allocating to 6 groups (ITC, ITL, ITLSN, IVC, IVL, IVLSN) for another 8 h. Survival time/rate (ST), and variables as biomarkers in lung physiology, histopathology, biochemistry, and pathophysiology were measured. The survival was LPS-route, but not dosing, dependent. Compared to the IVL, ITL had relatively higher ST, lung injury score (LIS), lower intrapulmonary phospholipid pools, mRNA expressions in surfactant proteins (SPs) and pulmonary vascular endothelial cell injury (VEI)-related variables. ITLSN had higher phospholipid pools but no improvement in ST, lung mechanics, LIS or mRNA expression of SPs, proinflammatory mediators and VEI-related variables. IVLSN had improved lung mechanics, LIS, phospholipid pools, and SP-A mRNA expression, but worse ST, metabolic acidosis, higher interleukin mRNA expression in the lungs, liver and kidney, suspected as sepsis-associated multiorgan involvement. Using the infant rabbit LPS-ALI model, we characterized the survival as LPS-route dependent, the lung impairment and response pattern in surfactant and iNO treatment ineffectiveness/failure, as pharmacotherapeutic response patterns, with causal implication pertinent to the underlying pathophysiology of experimental pediatric ARDS.

## Linked entities

- **Diseases:** pneumonia (MONDO:0005249), acute lung injury (MONDO:0006502), acute respiratory distress syndrome (MONDO:0006502)

## Full-text entities

- **Genes:** SP-A [NCBI Gene 100009044]
- **Diseases:** ARDS (MESH:D012128), pneumonia (MESH:D011014), ALI (MESH:D055371), lung injury (MESH:D055370), lung impairment (MESH:D009422), sepsis (MESH:D018805), multiorgan involvement (MESH:C564676), VEI (MESH:D057772), metabolic acidosis (MESH:D000138)
- **Chemicals:** nitric oxide (MESH:D009569), phospholipid (MESH:D010743), N (MESH:D009584), LPS (MESH:D008070), iNO (-), S (MESH:D013455)
- **Species:** Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12971534/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12971534/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12971534/full.md

---
Source: https://tomesphere.com/paper/PMC12971534